Every material Form 8-K Tempest Therapeutics, Inc. has filed with the SEC since October 19, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tempest Therapeutics said Chief Financial Officer Constance Ames resigned effective immediately on October 26, 2026, citing personal considerations unrelated to the company. The board appointed Stephanie Horn-Warnock as CFO, principal financial and accounting officer, treasurer and corporate secretary, also effective immediately, and she will work for the company as a consultant under an engagement letter dated October 28, 2026.
Constance Ames resigned as CFO and from all other company positions, effective immediately, for personal considerations unrelated to the company.
Stephanie Horn-Warnock, 37, was appointed CFO effective immediately on October 26, 2026.
Horn-Warnock previously was Vice President of Finance at ROM Technologies Inc. from January 2024 to September 2026.
Under her consulting engagement letter dated October 28, 2026, the company will pay $450 per hour plus expenses and an indirect cost allocation of 5.0% of total professional fees.
Tempest Therapeutics said its reconvened special meeting of stockholders lacked sufficient votes to approve a charter amendment that would replace specified supermajority voting requirements and permit stockholder action by written consent, so the meeting was adjourned again. The meeting will reconvene on November 12, 2026, and the proposal still requires at least 75% of the votes stockholders could cast in director elections, which matters because approval would change how shareholders can act.
Quorum was reached with 11,004,101 shares, or 74.3% of the 14,806,997 shares outstanding as of the May 28, 2026 record date, present or represented by proxy.
The proposal requires the affirmative vote of at least 75% of the votes all stockholders could cast in an annual election of directors.
The special meeting will reconvene on November 12, 2026, at 2:00 p.m. Eastern Time by live webcast.
The company has engaged Sodali & Co., a proxy solicitation firm, to help obtain sufficient votes.
Tempest Therapeutics appointed John Frederick as a Class III director effective October 13, 2026. Frederick previously served as Chief Financial Officer of Skillsoft Corp. from May 2025 to September 2026, and the filing describes his board term as running until the 2027 annual meeting.
Board appointment effective October 13, 2026; term runs until the Company's 2027 annual meeting of stockholders
Frederick to receive an initial option award to purchase 25,000 shares of common stock under the 2023 Equity Incentive Plan
Frederick was CFO of Skillsoft Corp. (NYSE: SKIL) from May 2025 to September 2026
Press release announcing the appointment issued October 14, 2026 and furnished as Exhibit 99.1
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tempest Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →